Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/60614
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sarana Boonbaichaiyapruck | en_US |
dc.contributor.author | Sayan Cheepudomwit | en_US |
dc.contributor.author | Pradit Panjavenin | en_US |
dc.contributor.author | Taworn Suthichaiyakul | en_US |
dc.contributor.author | Worachart Moleelerkpoom | en_US |
dc.contributor.author | Thanawat Benjanuwatra | en_US |
dc.contributor.author | Bancha Sukanandachai | en_US |
dc.contributor.author | Adisai Buakhamsri | en_US |
dc.date.accessioned | 2018-09-10T03:46:08Z | - |
dc.date.available | 2018-09-10T03:46:08Z | - |
dc.date.issued | 2008-08-01 | en_US |
dc.identifier.issn | 01252208 | en_US |
dc.identifier.issn | 01252208 | en_US |
dc.identifier.other | 2-s2.0-50949101302 | en_US |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=50949101302&origin=inward | en_US |
dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/60614 | - |
dc.description.abstract | Background: LDL and hs-CRP are risk factors for vascular events and can be modified by Statin. Objective: To evaluate the baseline hs-CRP of a certain Thai population who would need Atorvastatin, to evaluate the dose response of Atorvastatin toward LDL and hs-CRP level, and to evaluate the efficacy and safety of different types of Atorvastatin. Material and Method: Subjects, who needed Statin therapy, were randomized to receive either 20 mg of Berlin (B)-Atorvastatin(R) or Pfizer(P)- Atorvastatin(R). The cross over took place after 8 weeks of therapy and continued for 16 weeks. Baseline blood tests were compared to 8 and 16 weeks. The effect of two brands of 20 mg Atorvastatin toward serum lipid, LFT, muscle enzyme and hs-CRP were compared. Results: One hundred and ten subjects aged between 20-75 years enrolled in the present study. Fifty-four and 56 patients were randomized to group A and B. Baseline total cholesterol, LDL, HDL, and TG were 251, 174, 55, and 160 mg/dl respectively. There was a wide variation of baseline hs-CRP level. One hundred and seven patients completed this 16 weeks study. Atorvastatin 20 mg lowered TC by 32%, LDL 44% and hs-CRP 10% at 16 weeks for the entire study (p < 0.003). The effect of either Atorvastatin the lipid profiles and hs-CRP were different. There was no significant change in LFT or muscle enzyme. Conclusion: Atorvastatin 20 mg has a dramatic effect on the lipid but moderate effect on CRP. The two different types of Atorvastatin (group A and B) have similar effect on both safety and efficacy. | en_US |
dc.subject | Medicine | en_US |
dc.title | Effect of Atorvastatin on LDL & hs-CRP in a selected Thai population | en_US |
dc.type | Journal | en_US |
article.title.sourcetitle | Journal of the Medical Association of Thailand | en_US |
article.volume | 91 | en_US |
article.stream.affiliations | Mahidol University | en_US |
article.stream.affiliations | King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University | en_US |
article.stream.affiliations | Police General Hospital | en_US |
article.stream.affiliations | Chiang Mai University | en_US |
article.stream.affiliations | Maharat Nakhon Si Thammarat Hospital | en_US |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.